PEPTIDES IN ONCOLOGY
\nThe theme for this year's Boulder Peptide Symposium is Peptides in Oncology. While the use of peptides as cancer killing agents is one obvious use, peptides are also used as diagnostic markers and by extension homing beacons to carry cytotoxic agents to cancer cells. With recent advances in technology peptides can now also penetrate the cell membrane to access intracellular binding sites. As such peptides can function either as a cell penetrating agents or be used to modulate internal signalling pathways by binding to selective targets. Finally peptides are also being evaluated as components of subunit vaccines to treat cancer. Presentations and panel discussions at the symposium shall highlight advances in these areas.
ABOUT THE BOULDER PEPTIDE SYMPOSIUM
The Boulder Peptide Symposium seeks to bring together key decision leaders from both industry and academia to discuss the future of peptide therapeutics. Peptide therapeutics are potent and highly selective yet their development into effective treatments can be challenged by limited delivery routes, product stability, manufacturing challenges and an evolving regulatory landscape. BPS is the key forum where these challenges will be identified, discussed, and one day—addressed.
Short presentations from companies developing new peptides or related technologies.
Session I - Peptides in the Clinic
Updates on development programs for therapeutic peptides
Session II - Peptide Drug Delivery and Formulation
Presentations on improving half-life, oral and parenteral delivery systems and interesting peptide formulation challenges
Session III - Advances in Peptide Chemistry and Analytics
Highlights of recent advances in peptide synthetic methods and analytical techniques